RDD Pharma to acquire Naia Rare Diseases — 3 insights

RDD Pharma entered into a letter of intent to acquire Naia Rare Diseases in a move to boost its gastrointestinal drug pipeline.

What you should know:

1. Naia is developing a short bowel syndrome treatment and has other GI drugs in the pipeline.

2. RDD Pharma expects to close the deal after its merger with Innovate Biopharmaceuticals closes, forming 9 Meters Biopharma.

3. Naia will receive a combination of cash and shares in 9 Meters Biopharma if both deals close.

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast